- Home
- ILLRW vs ICUCW Comparison
ILLRW vs ICUCW Comparison
Compare ILLRW & ICUCW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ILLRW
- ICUCW
- Stock Information
- Founded
- ILLRW 2015
- ICUCW N/A
- Country
- ILLRW United States
- ICUCW United States
- Employees
- ILLRW N/A
- ICUCW 19
- Industry
- ILLRW Investment Managers
- ICUCW Biotechnology: Pharmaceutical Preparations
- Sector
- ILLRW Finance
- ICUCW Health Care
- Exchange
- ILLRW Nasdaq
- ICUCW Nasdaq
- Market Cap
- ILLRW N/A
- ICUCW N/A
- IPO Year
- ILLRW N/A
- ICUCW 2021
- Fundamental
- Price
- ILLRW $0.10
- ICUCW $0.03
- Analyst Decision
- ILLRW
- ICUCW
- Analyst Count
- ILLRW 0
- ICUCW 0
- Target Price
- ILLRW N/A
- ICUCW N/A
- AVG Volume (30 Days)
- ILLRW 40.5K
- ICUCW N/A
- Earning Date
- ILLRW 04-25-2025
- ICUCW N/A
- Dividend Yield
- ILLRW N/A
- ICUCW N/A
- EPS Growth
- ILLRW N/A
- ICUCW N/A
- EPS
- ILLRW N/A
- ICUCW N/A
- Revenue
- ILLRW $45,244,000.00
- ICUCW N/A
- Revenue This Year
- ILLRW N/A
- ICUCW N/A
- Revenue Next Year
- ILLRW N/A
- ICUCW N/A
- P/E Ratio
- ILLRW N/A
- ICUCW N/A
- Revenue Growth
- ILLRW N/A
- ICUCW N/A
- 52 Week Low
- ILLRW $0.14
- ICUCW N/A
- 52 Week High
- ILLRW $0.16
- ICUCW N/A
- Technical
- Relative Strength Index (RSI)
- ILLRW N/A
- ICUCW N/A
- Support Level
- ILLRW N/A
- ICUCW N/A
- Resistance Level
- ILLRW N/A
- ICUCW N/A
- Average True Range (ATR)
- ILLRW 0.00
- ICUCW 0.00
- MACD
- ILLRW 0.00
- ICUCW 0.00
- Stochastic Oscillator
- ILLRW 0.00
- ICUCW 0.00
About ILLRW Triller Group Inc. Warrant
Triller Group Inc is a us-based company that operates its businesses through Triller Corp which operates as a technology platform and AGBA Group Holding Limited operates as an insurance and wealth distribution platform.
About ICUCW SeaStar Medical Holding Corporation Warrant
SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. The Company is comprised of a single reportable segment, which is its Device Segment.